Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres-Reference-Cited by-同舟云学术

Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres

Published:2024-06-14 Issue: Volume: Page:
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Dalla Costa Gloria¹^ORCID,Leocani Letizia¹^ORCID,Pisa Marco¹,Croese Tommaso²,Martinelli Vittorio³,Moiola Lucia³^ORCID,Sangalli Francesca³,Colombo Bruno³,Haghikia Aiden⁴,Gold Ralf⁴,Furlan Roberto²^ORCID,Comi Giancarlo⁵

Affiliation:

1. Vita-Salute San Raffaele University, Milan, Italy

2. Neuroimmunology Research Unit, San Raffaele Hospital, Milan, Italy

3. Department of Neurology, San Raffaele Hospital, Milan, Italy

4. Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany

5. Vita-Salute San Raffaele University, Milan, Italy/Multiple Sclerosis Center, Casa di Cura Igea, Milan, Italy

Abstract

Background: While John Cunningham virus (JCV) is known to cause neuronal damage in progressive multifocal leukoencephalopathy (PML) among natalizumab-treated MS patients, its association with axonal loss in non-PML conditions remains unclear. Methods: In a cohort of 128 natalizumab-treated MS patients, serum neurofilament (sNfL) levels and JCV antibody titres were measured. Results: Among 128 patients (mean age = 38.4 years, 71.9% female), 51 (40%) were JCV positive. NfL levels increased by 15.3% for JCV index <0.7 (95% confidence interval [CI] = 0.963–1.381), by 18.6% for index 0.7–1.5 (95% CI = 1.009–1.394) and by 21.1% for index >1.5 (95% CI = 1.040–1.409) compared to JCV negative patients. Conclusion: These findings indicate a potential link between JCV burden and neuroaxonal degeneration in natalizumab-treated MS patients.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/13524585241260977

Reference12 articles.

1. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2. Anti- 4 integrin therapy for multiple sclerosis: Mechanisms and rationale

3. Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy

4. Anti-JC virus antibody titres increase over time with natalizumab treatment

5. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JC virus or extended interval dosing? More data are needed;Multiple Sclerosis Journal;2024-09-06